Accretion Nutraveda cash flow held to Rs 1.14 crore

Accretion Nutraveda Limited reported Rs 1.14 crore of net operating cash flow for the period ended September 30, 2026, against profit after tax of Rs 4.73 crore. A Rs 5.14 crore increase in receivables and a Rs 2.55 crore increase in inventories absorbed cash, while cash and cash equivalents declined to Rs 14.89 lakh.

Why was Accretion Nutraveda's operating cash flow Rs 1.14 crore?

Accretion Nutraveda generated Rs 1.14 crore of net cash from operating activities because Rs 6.26 crore of operating profit before working-capital changes was reduced by movements in operating assets and Rs 89.23 lakh of income tax. Profit before tax was Rs 5.69 crore for the period ended September 30, 2026, and Rs 40.59 lakh of finance costs plus Rs 16.69 lakh of depreciation added Rs 57.27 lakh to that measure.

The difference between earnings and cash flow was principally a working-capital effect in the September 2026 period. Accretion Nutraveda reported profit after tax of Rs 4.73 crore, compared with Rs 2.38 crore for the half year ended September 30, 2025, while revenue from operations increased to Rs 29.44 crore from Rs 14.06 crore. The cash-flow statement provides the year ended March 31, 2026 as its comparator, when net operating cash flow was an outflow of Rs 16.89 crore.

Cash generated from operations before tax was Rs 2.03 crore in the September 2026 period, compared with a cash outflow of Rs 15.75 crore in the year ended March 2026. The March-year figure included Rs 22.76 crore of net working-capital outflows, whereas the September-period cash-flow statement records a smaller net drag after a Rs 3.97 crore reduction in other current assets and a Rs 39.06 lakh reduction in other non-current assets.

How much cash did receivables and inventories absorb?

Receivables and inventories absorbed Rs 7.69 crore of cash in the period ended September 30, 2026, comprising Rs 5.14 crore for receivables and Rs 2.55 crore for inventories. These were the two largest stated operating cash outflows in Accretion Nutraveda's cash-flow statement, exceeding the Rs 1.14 crore net cash generated from operating activities after tax.

Trade receivables stood at Rs 13.25 crore on September 30, 2026, up from Rs 8.11 crore on March 31, 2026, while inventories rose to Rs 11.55 crore from Rs 8.99 crore. The increases of about Rs 5.14 crore and Rs 2.55 crore in the balance sheet align with the corresponding cash-flow movements, showing that higher reported sales and profit were accompanied by more funds held in customer balances and stock.

Other current assets partly offset those uses of cash, producing a Rs 3.97 crore cash inflow in the September period as their balance fell to Rs 6.12 crore from Rs 10.10 crore at March 31, 2026. The cash-flow statement also reports Rs 75 lakh used in short-term loans and advances, a Rs 6.58 lakh increase in payables, a Rs 2.23 lakh decrease in current liabilities and a Rs 20.05 lakh decrease in short-term provisions.

Where did Accretion Nutraveda deploy investing cash?

Accretion Nutraveda used Rs 5.68 crore in investing activities in the period ended September 30, 2026, consisting of Rs 3.43 crore for property, plant and equipment and Rs 2.26 crore of capital advances. That investment outflow was larger than the Rs 1.14 crore operating inflow and was the principal cash use reported for the September period.

Property, plant and equipment increased to Rs 4.92 crore at September 30, 2026 from Rs 1.66 crore at March 31, 2026. In the year ended March 31, 2026, the company reported Rs 8.45 lakh of property, plant and equipment purchases and Rs 6.95 crore of capital advances, producing a Rs 7.03 crore net investing cash outflow for that year.

The initial public offering, or IPO, proceeds disclosure identifies machinery purchases for an existing manufacturing unit and a new manufacturing setup as approved uses. Of the Rs 24.77 crore IPO proceeds, Accretion Nutraveda reported September-period utilisation of Rs 3.52 crore for automation machinery, Rs 2.78 crore for machinery in the new setup and Rs 25.59 lakh for working-capital requirements. Total IPO utilisation was Rs 24.77 crore by September 30, 2026, with no balance stated to remain deployed.

How did Accretion Nutraveda fund its cash requirements?

Accretion Nutraveda recorded Rs 3.42 crore of net financing cash inflow for the period ended September 30, 2026, led by Rs 2.75 crore of net short-term borrowings and Rs 1.07 crore of net long-term borrowings. Finance costs of Rs 40.59 lakh were included as a financing cash outflow, and the company reported no proceeds from issue of share capital in the period.

The combination of Rs 1.14 crore of operating cash inflow and Rs 3.42 crore of financing inflow produced Rs 4.56 crore before investing activities. This was below the Rs 5.68 crore investing outflow, resulting in a Rs 1.13 crore net reduction in cash and cash equivalents. The reported movement reconciles from an opening cash balance of Rs 1.28 crore to Rs 14.89 lakh at September 30, 2026.

Long-term borrowings in the balance sheet rose to Rs 4.85 crore at September 30, 2026 from Rs 3.78 crore at March 31, 2026. The cash-flow statement's Rs 1.07 crore net proceeds from long-term borrowings is therefore one disclosed source of funding during the period, alongside the Rs 2.75 crore of net short-term borrowing proceeds.

What changed in Accretion Nutraveda's balance sheet by September 2026?

Accretion Nutraveda's total assets increased to Rs 50.25 crore at September 30, 2026 from Rs 41.79 crore at March 31, 2026. Current assets rose to Rs 41.82 crore from Rs 36.23 crore, led by higher receivables and inventories, while non-current assets increased to Rs 8.43 crore from Rs 5.57 crore as property, plant and equipment reached Rs 4.92 crore.

The mix of current assets changed during the six months. Cash and cash equivalents fell to Rs 14.89 lakh from Rs 1.28 crore, whereas trade receivables rose by Rs 5.14 crore and inventories by Rs 2.55 crore. Short-term loans and advances were Rs 10.76 crore at September 30, 2026, compared with Rs 7.75 crore at March 31, while other current assets declined by Rs 3.97 crore.

Shareholders' funds were Rs 40.20 crore at September 30, 2026, compared with Rs 35.47 crore at March 31, 2026. Reserves and surplus increased to Rs 32.96 crore from Rs 28.23 crore over the same dates. The September 2026 financial results and statements were unaudited, reviewed by the Audit Committee and approved by the board on October 31, 2026.

Conclusion

Accretion Nutraveda's September 2026 figures show that Rs 4.73 crore of profit after tax translated into Rs 1.14 crore of operating cash flow after Rs 7.69 crore was absorbed by receivables and inventories. Financing inflows of Rs 3.42 crore supported investment cash use of Rs 5.68 crore, but cash and cash equivalents still declined to Rs 14.89 lakh.

The next item to watch is the effect of machinery spending for automation at the existing unit and the new manufacturing setup, for which the company reported completing the Rs 8.03 crore aggregate IPO allocation by September 30, 2026. The filing does not disclose a later cash-flow target or timetable, leaving subsequent results to show how receivables, inventories and cash balances develop after the deployment.